Related Topics News -

     
 Title only   |   Print 
     
中生製藥創新藥庫莫西利聯合方案達到預設主要終點

2026-06-02T  
《大行》大摩降中生製藥目標價至7.8元 評級「增持」

2026-06-01T  
中生製藥於美國臨床腫瘤學會披露臨床研究數據

2026-06-01T  
中生製藥TQB6411臨床研究顯示有效劑量下呈現良好安全性特徵

2026-06-01T  
中生製藥創新藥維特柯妥拜單抗臨床研究展現出令人鼓舞抗腫瘤活性

2026-06-01T  
中生製藥創新藥納地美定獲國家藥監局批准上市

2026-05-29T  
中生製藥治療乙肝藥物披露兩項臨床數據

2026-05-29T  
中生製藥TQB3454片「IDH1抑制劑」獲納入優先審評審批程序

2026-05-28T  
中生製藥於歐洲肝病學會年會披露Kylo-0603臨床研究數據

2026-05-27T  
中生製藥披露創新藥M701兩項臨床數據

2026-05-22T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.